Cibus (NASDAQ:CBUS) Shares Down 1.4% – Time to Sell?

Cibus, Inc. (NASDAQ:CBUS) was down 1.4% on Monday . The stock traded as low as $1.89 and last traded at $2.05. Approximately 322,630 shares traded hands during trading, a decline of 11% from the average daily volume of 363,047 shares. The stock had previously closed at $2.08.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CBUS. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 price target on shares of Cibus in a report on Monday, December 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Cibus has a consensus rating of “Hold” and an average price target of $20.00.

Cibus Stock Performance

The firm has a market capitalization of $111.27 million, a PE ratio of -0.63 and a beta of 1.80. The firm’s 50-day moving average is $1.81 and its 200 day moving average is $1.55.

Cibus (NASDAQ:CBUS) last announced its earnings results on Thursday, November 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). Cibus had a negative return on equity of 133.90% and a negative net margin of 3,133.92%.The firm had revenue of $0.62 million for the quarter, compared to analyst estimates of $1.39 million. As a group, equities analysts anticipate that Cibus, Inc. will post -2.96 earnings per share for the current year.

Hedge Funds Weigh In On Cibus

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its holdings in shares of Cibus by 113.4% during the fourth quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock valued at $99,000 after purchasing an additional 18,885 shares during the period. AQR Capital Management LLC purchased a new position in Cibus during the 1st quarter worth approximately $73,000. FNY Investment Advisers LLC purchased a new position in Cibus during the 2nd quarter worth approximately $54,000. Warberg Asset Management LLC acquired a new stake in Cibus during the 2nd quarter valued at $41,000. Finally, Transce3nd LLC lifted its holdings in shares of Cibus by 29.1% in the second quarter. Transce3nd LLC now owns 52,656 shares of the company’s stock valued at $75,000 after purchasing an additional 11,861 shares in the last quarter. 33.81% of the stock is currently owned by institutional investors and hedge funds.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.